May 26, 2020
Medivir Appoints Yilmaz Mahshid as New CEO
May 06, 2020
FDA Grants MIV-818 Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma
May 05, 2020
Resolutions at the Annual General Meeting in Medivir on 5 May 2020
Apr 30, 2020
Medivir Receives Positive Opinion on Orphan Medicinal Drug Designation by the European Medicines Agency for MIV-818
Apr 15, 2020
Medivir Announces Departure of Chief Medical Officer
Mar 16, 2020
Medivir and Tango Therapeutics Sign License Agreement for Preclinical Asset
Mar 10, 2020
First Liver Cancer Patient Dosed in the MIV-818 Phase Ib Study
Mar 02, 2020
Medivir Presents Positive Data From the Completed Phase Ia Study With MIV-818 in Patients With Advanced Liver Cancer
Feb 13, 2020
Medivir AB: Year End Report January-December 2019
Jan 20, 2020
Medivir's Phase II Study of MIV-711 in Patients With Osteoarthritis Published in Annals of Internal Medicine
Dec 18, 2019
Investigator-initiated Phase II Clinical Study of Remetinostat Started in Patients With Squamous Cell Carcinoma
Dec 16, 2019
Futility Analysis Performed of the Phase II Combination Study with Birinapant and Keytruda® in Colorectal Cancer Patients
Dec 10, 2019
Medivir Receives the International Diamond Prize for Excellence in Quality
Nov 18, 2019
Medivir Reports Last Patient Recruited to the Phase Ia Study of MIV-818 in Liver Cancer Patients and Initial Dose Determined for phase Ib
Oct 30, 2019
Medivir Presents MIV-818 Data at AACR-NCI-EORTC in Boston
Oct 10, 2019
US National Cancer Institute Initiates Phase I Study of Treatment of Head and Neck Cancer Patients With Medivir's Birinapant and Radiation Therapy
Aug 28, 2019
Medivir AB - Interim Report January - June 2019
Jun 13, 2019
Selective Effect Signal on Liver Cancer Tissue in Phase Ia Study With MIV-818
Jun 04, 2019
Medivir to Present at the 2019 BIO International Convention
Jun 03, 2019
New Data From the Phase I Study of Birinapant in Combination With Keytruda® Presented at ASCO